Clinical and Molecular Hepatology

"Anna Di Sessa"

Capturing systemic disease burden in MASLD: Toward integrated liver–kidney–cardiovascular economic models: Reply to correspondence on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”: Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia del Giudice; Clin Mol Hepatol 2026;32(3):e447-e449.
Published online February 11, 2026; DOI: https://doi.org/10.3350/cmh.2026.0160

Letter to the Editor

Letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”: Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia del Giudice; Clin Mol Hepatol 2026;32(3):e291-e293.
Published online January 9, 2026; DOI: https://doi.org/10.3350/cmh.2025.1417

Citations

Citations to this article as recorded by

Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disea
Eileen L. Yoon, Jeong-Yeon Cho, Mimi Kim, Huiyul Park, Hye-Lin Kim, Dae Won Jun
Clinical and Molecular Hepatology.2026; 32(3): e415. CrossRef
Capturing systemic disease burden in MASLD: Toward integrated liver–kidney–cardiovascular economic models: Reply to correspondence on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic live
Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia del Giudice
Clinical and Molecular Hepatology.2026; 32(3): e447. CrossRef